Viking Therapeutics Files 8-K
Ticker: VKTX · Form: 8-K · Filed: Mar 26, 2024 · CIK: 1607678
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: VKTX
TL;DR
Viking Therapeutics filed a standard 8-K on 3/26. No major news.
AI Summary
Viking Therapeutics, Inc. filed an 8-K on March 26, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This filing serves as a routine update and does not appear to contain new material information that would immediately impact the company's stock price.
Risk Assessment
Risk Level: low — The filing is a routine 8-K and does not disclose any new material events, risks, or significant financial changes.
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Registrant
- March 26, 2024 (date) — Filing Date
FAQ
What is the primary purpose of this 8-K filing by Viking Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on a Regulation FD Disclosure and Financial Statements and Exhibits.
On what date was this 8-K filed?
This 8-K was filed on March 26, 2024.
What is the state of incorporation for Viking Therapeutics, Inc.?
Viking Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Viking Therapeutics, Inc.?
The principal executive office address is 9920 Pacific Heights Blvd, Suite 350, San Diego, California 92121.
Does this filing disclose any new material events or financial results?
Based on the provided text, this filing appears to be a routine report and does not explicitly disclose any new material events or specific financial results beyond standard reporting categories.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-03-26 07:08:14
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
Filing Documents
- vktx-20240326.htm (8-K) — 41KB
- vktx-ex99_1.htm (EX-99.1) — 82KB
- img201808844_0.jpg (GRAPHIC) — 4KB
- 0000950170-24-036151.txt ( ) — 255KB
- vktx-20240326.xsd (EX-101.SCH) — 30KB
- vktx-20240326_htm.xml (XML) — 5KB
01. Regulation FD
Item 7.01. Regulation FD. On March 26, 2024, Viking Therapeutics, Inc. issued a press release announcing results from its oral Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information furnished under this Item 7.01 (Regulation FD Disclosure) of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated March 26, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIKING THERAPEUTICS, INC. Date: March 26, 2024 By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)